Structured around discovery of novel vaccines and therapeutics for emerging infectious diseases, Integrated BioTherapeutics, Inc. (IBT) is a biotechnology company with a pipeline of promising product candidates for bacterial and viral infections. Consistently active in SBIR from soon after the firm was founded, Integrated BioTherapeutics is primarily focused on counter-measures against staphylococcal infections - in major part by targeting a variety of toxins produced by S. aureus - IBTs S. aureus vaccine, -- now spun off into Integrated BioTherapeutic Vaccines -- enteried the clinic in 2022. IBTs antiviral pipeline include unique Ebola and Marburg antibody therapeutics, vaccines for filoviruses and Nipah virus, and a strong discovery pipeline for emerging viruses. Further, IBT developed a novel antibody engineering technology for targeting anti-toxin antibodies to the surface of bacteria, integrating toxin neutralization with effector functions.
